Phenylcarbamate derivatives as formyl peptide receptor modulators

A compound of Formula I:

• wherein:
• R1 is optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C6-10 aryl, optionally substituted C3-8 cycloalkenyl, halogen, NR11R12, fluorinated C1-8 alkyl, perfluorinated C1-8 alkyl, —S(O)mR13, —C(O)R14 or —OR15;
• R2 is H, optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C6-10 aryl, optionally substituted C3-8 cycloalkenyl, halogen, NR11R12, fluorinated C1-8 alkyl, perfluorinated C1-8 alkyl, —S(O)mR13, —C(O)R14 or —OR15;
• R3 is H, optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C6-10 aryl, optionally substituted C3-8 cycloalkenyl, halogen, NR11R12, fluorinated C1-8 alkyl, perfluorinated C1-8 alkyl, —S(O)mR13, —C(O)R14 or —OR15;
• R4 is H, optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C6-10 aryl, optionally substituted C3-8 cycloalkenyl, halogen, NR11R12, fluorinated C1-8 alkyl, perfluorinated C1-8 alkyl, —S(O)mR13—C(O)R14 or —OR15;
• R5 is H, optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C6-10 aryl, optionally substituted C3-8 cycloalkenyl, halogen, NR11R12, fluorinated C1-8 alkyl, perfluorinated C1-8 alkyl, —S(O)mR13, —C(O)R14 or —OR15;
• R6 is H, optionally substituted C1-8 alkyl, optionally substituted heterocycle, (CH2)pCOOH, —(CH2)p—NH2, —(CH2)p—OH, —(CH2)p—SH, —(CH2)p—CONH2, —(CH2)p—CONH2, —CH(OH)CH3, —(CH2)pSCH3, —(CH2)pNH—C(═NH)(NH2) or —CH2C6-10aryl, wherein said —C6-10aryl is optionally substituted;
• R6a is H or optionally substituted C1-8 alkyl;
• R7 is H or optionally substituted C1-8 alkyl;
• R8 is H;
• R9 is H, optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
• R10 is —(CH2)nOR16, —(CH2)—S(O)2OH, —(CH2)nC(O)R17, —(CH2)nOS(O)2OH, (CH2)nNR18R19, —(CH2)—P(O)(OC1-6 alkyl)2, —(CH2)nP(O)(OC1-6 alkyl)OH, —(CH2)n—P(O)(OH)2 or optionally substituted heterocycle;
• R11 is H, optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
• R12 is H, optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl;
• R13 is H, optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C6-10 aryl, OH or optionally substituted C3-8 cycloalkenyl;
• R14 is optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C6-10 aryl, optionally substituted C3-8 cycloalkenyl or —OR15;
• R15 is H or optionally substituted C1-8 alkyl;
• R16 is H, —C(O)(C1-8 alkyl) or optionally substituted C1-8 alkyl;
• R17 is OH, —OC1-8 alkyl or C1-8 alkyl;
• R18 is selected from the group consisting of H, optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C6-10 aryl, optionally substituted C3-8 cycloalkenyl, —C(O)R17 and —S(O)2N(C1-8 alkyl)2;
• R19 is selected from the group consisting of H, optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C6-10 aryl, or optionally substituted C3-8 cycloalkenyl, —C(O)R17 and —S(O)2N(C1-8 alkyl)2;
• with a proviso when R10 is —(CH)nC(O)R17 and R17 is C1-8 alkyl, then R9 is H;
• p is 1, 2 or 3;
• n is 0, 1, 2, 3, 4, 5, 6, 7 or 8;
• and
• m is 0, 1 or 2;
• wherein
• each C1-8 alkyl substituent is independently selected from the group consisting of halogen, hydroxyl, —OC1-8alkyl, C3-8cycloalkyl, amino, heterocycle, C6-10aryl, carboxylic acid, phosphonic acid, sulphonic acid, phosphoric acid, nitro, amide, sulfonamide, sulfonamide and carboxylate ester;
• each C3-8 cycloalkyl substituent is independently selected from the group consisting of halogen, hydroxyl, sulfonyl C1-8 alkyl, sulfoxide C1-8 alkyl, sulfonamide, nitro, —OC1-8 alkyl, —SC1-8 alkyl groups, —C1-8 alkyl, ketone, alkylamino, amino, C6-10 aryl and C3-8 cycloalkyl;
• each heterocycle substituent is independently selected from the group consisting of halogen, hydroxyl, —OC1-8 alkyl, sulfonyl C1-8 alkyl, sulfoxide C1-8 alkyl, nitro, —SC1-8 alkyl, —C1-8 alkyl, ketone, alkylamino, amino, C6-10 aryl and C3-8 cycloalkyl;
• each C6-10 aryl substituent is independently selected from the group consisting of halogen, hydroxyl, sulfonyl C1-8 alkyl, sulfoxide C1-8 alkyl, sulfonamide, carboxylic acid, C1-8 alkyl carboxylate (ester), amide, nitro, —OC1-6 alkyl, —SC1-8 alkyl, —C1-8 alkyl, ketone, alkylamino, amino and C3-8 cycloalkyl;
• and
• each C3-8 cycloalkenyl substituent is independently selected from the group consisting of halogen, hydroxyl, sulfonyl C1-8 alkyl, sulfoxide C1-8 alkyl, nitro, —OC1-6 alkyl, —SC1-6 alkyl, —C1-6 alkyl, ketone, alkylamino, amino, C6-10 aryl and C3-8 cycloalkyl;
• or an enantiomer, diastereomer or tautomer thereof;
• or a pharmaceutically acceptable salt of any of the foregoing.